CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...

The diffusion capacity of the lung for carbon monoxide (DLCO) is used to measure the body's ability to transfer oxygen across the alveolar-capillary membrane. [1] Internists use this test to identify ...

Background—Pulmonary diffusing capacity for carbon monoxide (Dlco), alveolar capillary membrane diffusing capacity (Dm), and pulmonary capillary blood volume (Vc) are all significantly reduced after ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Impairment of lung diffusion capacity, which correlated ...

You have full access to this article via your institution. The reduction in the patients’ diffusing capacity was marked, and for women and men, respectively, DLCO was 6.09 and 8.56 mmol/kPa/min ...

ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Lung diffusing capacity for nitric oxide ...

February 21, 2011 (Orlando, Florida) — In patients taking bleomycin for germ cell tumors, the use of lung function testing to monitor for drug-induced pneumonitis is controversial. A new study ...

Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had ...

CHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that ...